TY - JOUR
T1 - De novo drug delivery modalities for treating damaged hearts
T2 - Current challenges and emerging solutions
AU - Alvi, Syed Baseeruddin
AU - Ahmed, Salmman
AU - Sridharan, Divya
AU - Naseer, Zahra
AU - Pracha, Nooruddin
AU - Wang, Henry
AU - Boudoulas, Konstantinos Dean
AU - Zhu, Wuqiang
AU - Sayed, Nazish
AU - Khan, Mahmood
N1 - Funding Information:
This publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R01HL136232 (MK).
Publisher Copyright:
© 2021 Alvi, Ahmed, Sridharan, Naseer, Pracha, Wang, Boudoulas, Zhu, Sayed and Khan.
PY - 2021
Y1 - 2021
N2 - Cardiovascular disease (CVD) is the leading cause of mortality, resulting in approximately one-third of deaths worldwide. Among CVD, acute myocardial infarctions (MI) is the leading cause of death. Current treatment modalities for treating CVD have improved over the years, but the demand for new and innovative therapies has been on the rise. The field of nanomedicine and nanotechnology has opened a new paradigm for treating damaged hearts by providing improved drug delivery methods, specifically targeting injured areas of the myocardium. With the advent of innovative biomaterials, newer therapeutics such as growth factors, stem cells, and exosomes have been successfully delivered to the injured myocardial tissue, promoting improvement in cardiac function. This review focuses on three major drug delivery modalities: nanoparticles, microspheres, and hydrogels, and their potential for treating damaged hearts following an MI.
AB - Cardiovascular disease (CVD) is the leading cause of mortality, resulting in approximately one-third of deaths worldwide. Among CVD, acute myocardial infarctions (MI) is the leading cause of death. Current treatment modalities for treating CVD have improved over the years, but the demand for new and innovative therapies has been on the rise. The field of nanomedicine and nanotechnology has opened a new paradigm for treating damaged hearts by providing improved drug delivery methods, specifically targeting injured areas of the myocardium. With the advent of innovative biomaterials, newer therapeutics such as growth factors, stem cells, and exosomes have been successfully delivered to the injured myocardial tissue, promoting improvement in cardiac function. This review focuses on three major drug delivery modalities: nanoparticles, microspheres, and hydrogels, and their potential for treating damaged hearts following an MI.
KW - Clinical trials
KW - Drug delivery
KW - Heart failure
KW - Myocardial infarction
KW - Nanoparticles
UR - http://www.scopus.com/inward/record.url?scp=85121737607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121737607&partnerID=8YFLogxK
U2 - 10.3389/fcvm.2021.742315
DO - 10.3389/fcvm.2021.742315
M3 - Review article
AN - SCOPUS:85121737607
SN - 2297-055X
VL - 8
JO - Frontiers in Cardiovascular Medicine
JF - Frontiers in Cardiovascular Medicine
M1 - 742315
ER -